Zai Lab Limited (ZLAB) AI Stock Analysis

Zai Lab Limited is a biopharmaceutical company founded in 2013 and headquartered in Shanghai, China, operating primarily in Mainland China and Hong Kong. It develops and commercializes innovative therapies targeting oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial offerings include Zejula, Optune, NUZYRA, and Qinlock. The company's pipeline includes investigational therapies such as Odronextamab for lymphomas, Repotrectinib for targeted cancer mutations, Margetuximab for breast and gastroesophageal cancers, Adagrasib for KRAS-G12C-mutated cancers, Bemarituzumab for gastric cancers, Efgartigimod for autoimmune disorders, and KarXT for psychiatric conditions.

Revenue increased from $144.3M in FY2021 to $215.0M in FY2022, $266.7M in FY2023, $399.0M in FY2024, and $460.2M in FY2025, reflecting a 5-year revenue CAGR of 56.5% from FY2020 to FY2025. Annual net losses narrowed over this period from -$704.5M in FY2021 to -$175.5M in FY2025, with EPS improving from -$7.58 to -$1.61. Gross margin shifted from 63.8% in FY2021 to 58.5% in FY2025, while operating margin improved from -485.1% to -48.6%. Over the trailing twelve months, revenue reached $449.6M with an operating margin of -72.0% and a net margin of -41.9%. In the latest quarter ended June 30, 2026, quarterly revenue fell 3.3% year-over-year.

As of June 30, 2026, Zai Lab held $617.5M in cash and short-term investments and $254.6M in total debt, yielding net cash of $362.9M. The company reported a current ratio of 2.13 and a debt-to-equity ratio of 0.42 against shareholders' equity of $607.0M. Total assets stood at $1.07B. Operating cash flow for FY2025 was -$150.8M, and free cash flow was -$164.2M after capital expenditures of $13.4M.

Zai Lab has a market cap of $2.60B and an enterprise value of $2.65B. The stock trades at a price-to-sales multiple of 5.8x and an EV-to-revenue multiple of 5.9x, above the 4.1x price-to-sales median of its US-listed Healthcare peers. Its price-to-book ratio is 4.9x. Over the past year, Zai Lab declined 19.6%, while the S&P 500 (SPY) gained 16.8%. Over five years, the stock dropped 77.3% compared to an 83.0% gain for the benchmark index. Year-to-date return stands at 31.5%.

Wall Street analysts track Zai Lab with 9 Strong Buy, 2 Buy, and 1 Hold ratings. The mean price target of $33.14 sits 42.9% above the last close of $23.19. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$2.20 and revenue of $436.5M. For the next fiscal year, 10 analysts estimate revenue of $552.1M and EPS of -$2.11. The company beat EPS estimates in 1 of the last 4 quarters, with the next earnings report scheduled for November 5, 2026.

This page is an AI-written research summary of Zai Lab Limited (ZLAB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ZLAB income statement, ZLAB balance sheet, ZLAB key metrics, ZLAB analyst forecast, ZLAB chart. See the ZLAB stock overview for the latest quote and news.